ResApp Health develops digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
What? ~ ResApp Health develops digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
The company is creating affordable, clinically validated and regulatory approved diagnostic tools that only require a smartphone.
Cough is the most common single reason for visiting a doctor, with hundreds of millions of people diagnosed every year with acute respiratory conditions such as bronchiolitis and pneumonia.
Where? ~ www.resapphealth.com.au
Who? ~ ResApp was founded in September 2014 by UniQuest (the main commercialisation company of the University of Queensland) and Brian Leedman.
ResApp is commercialising technology developed by Udantha Abeyratne from the University of Queensland.
The team has been engaged in the research since 2009 and been funded by the Bill and Melinda Gates Foundation, The University of Queensland and UniQuest. ResApp Health Limited is now led by Dr Tony Keating.
Quotations ~ We are building the next generation of digital health solutions, providing the power of a clinically accurate, instant respiratory disease diagnosis to anybody who owns a smartphone.
This will significantly increase the effectiveness of telehealth and provide a convenient way to diagnose, treat and manage some of the most commonly seen diseases
$ ~ ResApp successfully raised $4m through an oversubscribed prospectus in July 2015 and is now listed on the ASX (ASX: RAP).
Market ~ Preliminary results from ResApp's second clinical study (currently under way at both the Joondalup Health Campus and the Princess Margaret Hospital) are due by the end of September.
Telehealth is one of the fastest growing industries in the US, and Deloitte predicted that there would be 75 million telehealth visits in 2014.
ResApp is currently ranked #37on the BNiQ Total Shareholder Returns list with 186% gain (year to July 31 2015).